Descrizione del progetto
Nuovo trattamento di combinazione farmacologica per la tubercolosi
La tubercolosi (TBC) è ancora la malattia infettiva più mortale al mondo e la TBC multiresistente rappresenta una seria minaccia per la salute globale. Le opzioni di trattamento sono limitate e spesso associate a molti effetti negativi dei farmaci. L’obiettivo complessivo del progetto RespiriTB, finanziato dall’UE, è trovare nuovi farmaci candidati per un trattamento combinato efficace contro la TBC e la TBC multifarmaco-resistente. La combinazione di farmaci mirerà al metabolismo energetico del Mycobacterium tuberculosis (Mtb), utilizzando inibitori del percorso respiratorio del Mtb scoperti di recente. Si concentrerà anche su fattori dell’ospite essenziali per la sopravvivenza intracellulare del Mtb. Il progetto presenta un piano completo per trovare nuove strategie per combattere la TBC, abbreviare i tempi di trattamento e ridurre l’incidenza della resistenza ai farmaci.
Obiettivo
Despite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the world’s leading infectious disease killer worldwide. In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health. Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs. Moreover, due to the long treatment duration, compliance is low leading to more AMR in TB. Thus, there is an acute need for the development of a novel combination regimen with an indication for effective, shorter, and safer treatment of all forms of TB. The overall objective of RESPIRI-TB is to find new drug candidates as potential components of a new, more efficient combination drug regimen against TB that is less prone to resistance and allows shortening of treatment duration for TB, and multidrug-resistant TB. Such a drug combination will synergistically target the energy metabolism of Mtb or complementary targets. To achieve this, we will advance recently discovered inhibitors of the Mtb respiratory pathway. In addition, we will target the Mtb specific molecular mechanism that reduces reactive oxygen species in the cell. Finally, we will also target host-factors that are essential for the intracellular survival of Mtb. Together, we present a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce chances of drug resistance.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programma(i)
Invito a presentare proposte
H2020-JTI-IMI2-2018-16-single-stage
Vedi altri progetti per questo bandoMeccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
2333 ZA Leiden
Paesi Bassi